Empirically Defining Treatment Response and Remission in Body Dysmorphic Disorder Using a Short Self-Report Instrument.

Appearance anxiety inventory Body dysmorphic disorder Optimal cutoffs Signal detection analysis

Journal

Behavior therapy
ISSN: 1878-1888
Titre abrégé: Behav Ther
Pays: England
ID NLM: 1251640

Informations de publication

Date de publication:
07 2021
Historique:
received: 06 03 2020
revised: 13 10 2020
accepted: 15 10 2020
entrez: 17 6 2021
pubmed: 18 6 2021
medline: 22 6 2021
Statut: ppublish

Résumé

Determining response or remission status in body dysmorphic disorder (BDD) usually requires a lengthy interview with a trained clinician. This study sought to establish empirically derived cutoffs to define treatment response and remission in BDD using a brief self-report instrument, the Appearance Anxiety Inventory (AAI). Results from three clinical trials of BDD were pooled to create a sample of 123 individuals who had received cognitive-behavioral therapy for BDD, delivered via the Internet. The AAI was compared to gold-standard criteria for response and remission in BDD, based on the clinician-administered Yale-Brown Obsessive Compulsive Scale, modified for BDD (BDD-YBOCS), and evaluated using signal detection analysis. The results showed that a ≥ 40% reduction on the AAI best corresponded to treatment response, with a sensitivity of 0.71 and a specificity of 0.84. A score ≤ 13 at posttreatment was the optimal cutoff in determining full or partial remission from BDD, with a sensitivity of 0.75 and a specificity of 0.88. These findings provide benchmarks for using the AAI in BDD treatment evaluation when resource-intensive measures administered by clinicians are not feasible.

Identifiants

pubmed: 34134823
pii: S0005-7894(20)30145-3
doi: 10.1016/j.beth.2020.10.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

821-829

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Oskar Flygare (O)

Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services. Electronic address: oskar.flygare@ki.se.

Long-Long Chen (LL)

Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services.

Lorena Fernández de la Cruz (L)

Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services.

Christian Rück (C)

Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services.

Erik Andersson (E)

Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services.

Jesper Enander (J)

Centre for Psychiatry Research, Karolinska Institutet and CAP Research Centre, Stockholm Health Care Services.

David Mataix-Cols (D)

Centre for Psychiatry Research, Karolinska Institutet and CAP Research Centre, Stockholm Health Care Services.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH